Enable Accessibility Enable Accessibility

About Takeda Canada

Conducting our business with high ethical standards

Takeda is a global pharmaceutical leader founded by Chobei Takeda I in 1781 in Osaka, Japan. For over 237 years, we’ve aimed to make an impact on patients’ lives by translating science into life-changing medicines. Our commitment to bringing better health and brighter futures to people around the world is built on a sustainable portfolio of innovative medicines.

Our Corporate Philosophy is unique to Takeda and is what distinguishes us from other companies. At Takeda, we conduct our business with high ethical and moral standards through the practical implementation of the corporate philosophy, "Takeda-ism". The four Takeda-ism values – integrity, fairness, honesty and perseverance are the foundation of our company and are what guide us in our work. With the patient at the centre, we deliver better health for Canadians through leading innovations in medicine.

Our passion for healthcare and commitment to improving lives will enable us to make the next 237 years healthier and brighter for people around the world.


Takeda Canada: An emerging agile specialty care provider focusing in gastroenterology and oncology

Takeda Canada is an emerging agile specialty care provider delivering better health for Canadians through leading innovations in gastroenterology and oncology.

Our top priority is the health of Canadians. Their well-being is central to our work and drives our commitment to deliver a diverse portfolio of innovative treatments in specialty care to meet their needs.

Our unwavering commitment to our patients, passion for innovation and deeply rooted collaborative spirit are what drives our patient-centric culture.


Patients motivate and inspire us to do more

Takeda’s long-standing presence and expertise in general medicine gastrointestinal health positions the company well to be a key player in specialty gastroenterology. Takeda Canada has already launched its first biologic treatment, ENTYVIO® and the company’s first patient support program, YOURVANTAGE™

Takeda Canada’s first oncology treatment, NINLARO®, is now available to Canadian patients. Takeda Oncology has more than 15 compounds in its pipeline.

Takeda Canada is also committed to ensuring the company’s established Primary Care products remain available for Canadian patients. More information about Our Medicines is available here.


Our Canadian roots run deep

Takeda established operations in Canada in 2009, however, the company’s history in Canada started in 1996 and now has over 125 employees across Canada. The company’s global history and strength gives Takeda Canada a solid foundation to build its operations and investments as it becomes an agile specialty healthcare company focused on gastroenterology and oncology.

In addition to the treatments we bring to Canadians under the Takeda name, many Takeda medicines have been helping patients in Canada for years through partnerships with other companies prior to establishing our own operations in Canada. Well-known and successful Takeda products have been available for many years through other companies by or under licence from Takeda including:

  • ACTOS® (pioglitazone hydrochloride)
  • ADCETRIS® (brentuximab vedotin)
  • ATACAND® (candesartan cilexetil)
  • LUPRON® (leuprolide acetate)
  • PREVACID® (lansoprazole)
  • TRINTELLIX® (vortioxetine)
  • VELCADE® (bortezomib)